Interim Data from Targeted Genetics' Phase I HIV/AIDS Vaccine Trial to Be Presented at Leading European AIDS Vaccine Meeting; V
30 8월 2006 - 3:00PM
Business Wire
Targeted Genetics Corporation (Nasdaq:TGEN) announced that Nathan
Clumeck, M.D., Ph.D., Head of the Department of Infectious
Diseases, St. Pierre University Hospital in Brussels, Belgium, will
present interim results today from a Phase I clinical trial of
tgAAC09, an investigational HIV/AIDS vaccine candidate based on
recombinant adeno-associated virus vector serotype 2 (AAV2). The
trials for tgAAC09 are being conducted in collaboration with the
International AIDS Vaccine Initiative (IAVI). The trial, enrolling
healthy volunteers who are not infected with HIV, was conducted in
Belgium and Germany, and is ongoing in India. Professor Clumeck is
a principal investigator for this study and will present this data
at the AIDS Vaccine 2006 Conference, taking place August 29 until
September 1, 2006, in Amsterdam, Netherlands. A second clinical
trial of tgAAC09 is ongoing in South Africa, Uganda and Zambia to
evaluate a higher dose and to systematically evaluate the utility
and optimal timing of boost vaccination. The Phase I trial is the
first ever to test a recombinant AAV-based vaccine and is primarily
designed to evaluate safety and tolerability of the vaccine at
escalating dose levels. The study is also designed to evaluate
immune responses following vaccination. No safety concerns were
identified and the vaccine was well tolerated. In a subset of the
volunteers receiving a single administration of the highest dose of
the vaccine, modest immune responses were observed. Further studies
are planned to determine the clinical relevance of this
observation. "We are very encouraged by the immune responses
observed in a subset of patients receiving the highest dose of
tgAAC09 in this study," said H. Stewart Parker, President and Chief
Executive Officer of Targeted Genetics. "This is the first human
evidence that an AAV-based vaccine can stimulate the immune system
to respond to HIV proteins. While these data require confirmation
and additional analysis, they provide critical insight into the
activity of tgAAC09 that will help inform our comprehensive
development program for AAV-based vaccines designed to protect
against HIV/AIDS. In conjunction with data from other trials
evaluating higher doses of tgAAC09 and a variety of dosing
schedules, these data support our efforts to develop a vaccine that
has the potential to impact the global HIV/AIDS pandemic." About
the Clinical Program The Phase I clinical trial is a double-blind,
placebo-controlled, dose-escalation safety study that also monitors
immune responses to the product candidate. The portion of the study
conducted in Belgium and Germany enrolled 50 volunteers who were in
good general health and not infected with HIV. The portion of the
trial being conducted in India enrolled 30 healthy HIV-negative
volunteers. Each volunteer received a single intramuscular
injection into the upper arm. A subset of volunteers also received
a second dose of the vaccine to determine if repeat dosing is safe,
and if it boosts immune responses. The Phase I trial in Germany,
Belgium and India is being conducted in collaboration with
researchers at Columbus Children's Research Institute and The
Children's Hospital of Philadelphia. A Phase II trial of a vaccine
based on AAV2 is being conducted in collaboration with the Chris
Hani Baragwanath Hospital, the Desmond Tutu Institute for HIV
Research and the University of Limpopo in South Africa; the Uganda
Virus Research Institute; and the Zambia Emory HIV Research
Project. This trial is being conducted in order to evaluate the
potential impact of a higher dose of tgAAC09 and boost vaccination
on the strength and duration of immune responses. About Targeted
Genetics Targeted Genetics Corporation is a biotechnology company
committed to the development and commercialization of innovative
targeted molecular therapies for the prevention and treatment of
inflammatory arthritis, HIV/AIDS and other acquired and inherited
diseases with significant unmet medical need. Targeted Genetics
uses its considerable knowledge and capabilities in the development
and manufacturing of gene delivery technologies to advance a
diverse product development pipeline. Its product development
efforts target inflammatory arthritis, HIV/AIDS, congestive heart
failure, Huntington's disease, and hyperlipidemia. To learn more
about Targeted Genetics, visit its website at
www.targetedgenetics.com. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: This release contains
forward-looking statements regarding the data to be collected in
this trial, the establishment or determination of efficacy
endpoints from the data collected in the trial, the timely and
complete accrual of patients in the trial and our ability to
commercialize tgAAC09 and other statements about our plans,
objectives, intentions and expectations. These statements, involve
current expectations, forecasts of future events and other
statements that are not historical facts. Inaccurate assumptions
and known and unknown risks and uncertainties can affect the
accuracy of forward-looking statements. Factors that could affect
our actual results include, but are not limited to, our ability to
obtain, maintain and protect our intellectual property, our ability
to raise capital when needed, our partners ability to recruit and
enroll suitable trial participants, our partners continued support
of this clinical program, the timing, nature and results of
research and clinical trials, potential development of alternative
technologies or more effective processes by competitors, and, our
ability to obtain and maintain regulatory or institutional
approvals, as well as other risk factors described in Item 1A. Risk
Factors in our report on Form 10-K for the year ended December 31,
2005, and updated in Item 1A. Risk Factors in our subsequent
reports on Form 10-Q. You should not rely unduly on these
forward-looking statements, which apply only as of the date of this
release. We undertake no duty to publicly announce or report
revisions to these statements as new information becomes available
that may change our expectations.
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024